A new sphingolipid, 4E, 6E, 2S, 3R-2-N-Docosanoyl-4,6-tetradecasphingadienine of Beauveria bassiana 101A having enhancement of the neurite outgrowth

摘要

PURPOSE: Provided is new sphingolipid, (4E, 6E, 2S, 3R)-2-N-Docosanoyl-4,6-tetradecasphingadienine which is isolated and purified from Beauveria bassiana 101A and has prevention and treatment effects on degenerative brain diseases. CONSTITUTION: New sphingolipid, (4E, 6E, 2S, 3R)-2-N-Docosanoyl-4,6-tetradecasphingadienine is isolated and purified from Beauveria bassiana 101A and has prevention and treatment effects on degenerative brain diseases. It is characteristically represented by the formula(1). A pharmaceutical preparation for prevention and treatment of brain diseases characteristically contains (4E, 6E, 2S, 3R)-2-N-Docosanoyl-4,6-tetradecasphingadienine as an active ingredient.